Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

The impact of planned parental follow‐up on compliance with opioids disposal following pediatric surgery
Adler, Adam C. , Bryant, Brittany E. , Baszynski, David, Lee, Andrew , Medellin, Eduardo , McCarthy, Jennifer , White, Andrea T. , Nathanson, Brian H. , Chandrakantan, Arvind , White, Andrea

Mayo Clinic

Pediatric Anesthesia | April 21, 2022 | Volume: 32 | Issue: 8 | Pages: 970-972

10.1111/pan.14467 | PMID 35445783 Get It

“It’s Like You Stuck a Pin in It:” African American/Black Patients Describe Cutaneous Toxicity From Epidermal Growth Factor Receptor Inhibitors
Martin, Nichole , Asiedu, Gladys B. , Jatoi, Aminah , Nguyen, Phuong L., Martin, Nichole A, Asiedu, Gladys, Jatoi, Aminah , Tran, Nguyen H. , Nguyen, Phuong , Le‐Rademacher, Jennifer

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | April 20, 2022 | Volume: 40 | Issue: 3 | Pages: 337-340

10.1177/10499091221092698 | PMID 35442101 Get It

Background: Epidermal growth factor receptor (EGFR) inhibitors cause cutaneous toxicity in over 90% of patients. Conceivably, healthcare providers could overlook such toxicity in African American/Black patients because of a darker complexion. This qualitative study sought to learn about such cutaneous signs and symptoms and, if present, to report them in patients’ own words. Methods: Any patient who self-identified as African American/Black and who had been prescribed an EGFR inhibitor was eligible. The current report focuses on patients’ responses to the following question, “What have you noticed since starting your cancer treatment (the EGFR inhibitor), any particular symptoms or reactions, positive or negative?” All interview data were audio-recorded, transcribed, and then independently coded and analyzed by two investigators. Results: Fifteen patients are the focus of this report, and all described cutaneous toxicity. Patients appeared troubled by the cosmetic aspect of these drug-induced skin changes, including their acneiform appearance, describing “little pimples with little, little pus in it.” Notable were comments on hyperpigmentation, “I’m a black person but…. became darker.” Furthermore, patients experienced physical symptoms: “it itches;” “it’s like you stuck a pin in it;” “stinging;” and “burning;”. Conclusion: Although cutaneous toxicity from EGFR inhibitors might be more difficult to visualize among darkly complected patients, the graphic descriptions offered in this qualitative study underscore the need for clinicians to heighten their awareness of such toxicity in African American/Black patients.
Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
Samson, Adel , West, Emma J. , Carmichael, Jonathan , Scott, Karen J. , Turnbull, Samantha , Kuszlewicz, Bethany, Dave, Rajiv , Peckham-Cooper, Adam , Tidswell, Emma, Kingston, Jennifer , Johnpulle, Michelle, Jennings, Victoria A. , Stojkowitz, Nicolas, Lusky, Monika, Prasad, Rajendra , Toogood, Giles J. , Bell, John C. , Twelves, Chris , Harrington, Kevin J. , Vile, Richard G. , Pandha, Hardev , Errington‐Mais, Fiona , Ralph, Christy , Newton, Darren , Anthoney, Alan , Melcher, Alan , Collinson, Fiona , Dave, Rajiv V , Bendjama, Kaidre , Bell, John , Twelves, Christopher , Errington-Mais, Fiona , Ralph, Christy , Newton, Darren J , Collinson, Fiona , Melcher, Alan A , Harrington, Kevin , Silva, Bárbara da , Auer, Rebecca

Mayo Clinic

Cancer Immunology Research | April 19, 2022 | Volume: 10 | Issue: 6 | Pages: 745-756

10.1158/2326-6066.cir-21-0171 | PMID 35439304 Get It

Abstract Improving the chances of curing patients with cancer who have had surgery to remove metastatic sites of disease is a priority area for cancer research. Pexa-Vec (Pexastimogene Devacirepvec; JX-594, TG6006) is a principally immunotherapeutic oncolytic virus that has reached late-phase clinical trials. We report the results of a single-center, nonrandomized biological end point study (trial registration: EudraCT number 2012-000704-15), which builds on the success of the presurgical intravenous delivery of oncolytic viruses to tumors. Nine patients with either colorectal cancer liver metastases or metastatic melanoma were treated with a single intravenous infusion of Pexa-Vec ahead of planned surgical resection of the metastases. Grade 3 and 4 Pexa-Vec–associated side effects were lymphopaenia and neutropaenia. Pexa-Vec was peripherally carried in plasma and was not associated with peripheral blood mononuclear cells. Upon surgical resection, Pexa-Vec was found in the majority of analyzed tumors. Pexa-Vec therapy associated with IFNα secretion, chemokine induction, and resulted in transient innate and long-lived adaptive anticancer immunity. In the 2 patients with significant and complete tumor necrosis, a reduction in the peripheral T-cell receptor diversity was observed at the time of surgery. These results support the development of presurgical oncolytic vaccinia virus-based therapies to stimulate anticancer immunity and increase the chances to cure patients with cancer.
Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region
Jordahl, Kristina M. , Shcherbina, Anna , Kim, Andre E. , Arndt, Volker , Baurley, James W. , Berndt, Sonja I. , Bishop, D. Timothy , Bouras, Emmanouil , Brenner, Hermann , Carreras‐Torres, Robert , Casey, Graham , Conti, David V. , Díez‐Obrero, Virginia , Dimou, Niki , Drew, David A. , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Gsur, Andrea , Harlid, Sophia , Harrison, Tabitha A. , Hoffmeister, Michael , Huyghe, Jeroen R. , Joshi, Amit D. , Li, Li , Nan, Hongmei , Nassir, Rami , Obón‐Santacana, Mireia , Ose, Jennifer , Pai, Rish K. , Papadimitriou, Nikos , Pardamean, Bens , Prentice, Ross L. , Rennert, Gad , Scacheri, Peter C. , Schmit, Stephanie L. , Slattery, Martha L. , Thibodeau, Stephen N. , Thomas, Duncan C. , Tian, Yu , Tsilidis, Konstantinos K. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Visvanathan, Kala , Vodička, Pavel , White, Emily , Woods, Michael O. , Wu, Anna H. , Zemlianskaia, Natalia , Chang‐Claude, Jenny , Gauderman, W. James , Kundaje, Anshul , Peters, Ulrike , Arndt, Volker , Bien, Stephanie A , Bishop, D Timothy , Brenner, Hermann , Buchanan, Daniel D , Campbell, Peter T , Carreras-Torres, Robert , Chan, Andrew T , Dampier, Christopher H , Dimou, Niki , Drew, David A , Figueiredo, Jane C , Giles, Graham G , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Hampel, Heather , Harlid, Sophia , Harrison, Tabitha A , Hidaka, Akihisa , Hoffmeister, Michael , Huyghe, Jeroen R , Larsson, Susanna C , Mahesworo, Bharuno , Moreno, Victor , Morrison, John L , Nassir, Rami , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Peoples, Anita R , Pharoah, Paul D P , Platz, Elizabeth A. , Potter, John D , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Schmit, Stephanie L , Schoen, Robert E , Slattery, Martha L , Stern, Mariana Carla , Thomas, Duncan C , Tian, Yu , Tsilidis, Konstantinos K , Ulrich, Cornelia M , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Visvanathan, Kala , Wolk, Alicja , Woods, Michael O , Chang-Claude, Jenny , Gauderman, W James , Hsu, Li , Kundaje, Anshul , Peters, Ulrike , Pardamean, Bens , Bouras, Emmanouil , Conti, David V , Nan, Hongmei , Obón-Santacana, Mireia , Papadimitriou, Nikos , Shcherbina, Anna , Vodicka, Pavel , Diez-Obrero, Virginia , Su, Yu-Ru , Lin, Yi , Wang, Jun , Qu, Conghui , Albanes, Demetrius , Bien, Stephanie A. , Buchanan, Daniel D. , Budiarto, Arif , Campbell, Peter T. , Cenggoro, Tjeng Wawan , Chan, Andrew T. , Dampier, Christopher H. , Devall, Matthew A M , Giles, Graham G. , Gunter, Marc J. , Hampel, Heather , Hidaka, Akihisa , Jenkins, Mark A. , Keku, Temitope O , Larsson, Susanna C. , Marchand, Loı̈c Le , Lewinger, Juan Pablo , Moreno, Vı́ctor , Morrison, John L. , Murphy, Neil , Newcomb, Polly A. , Palmer, Julie R. , Pharoah, Paul D.P. , Potter, John D. , Sakoda, Lori C. , Schoen, Robert E. , Tangen, Catherine M. , Ulrich, Cornelia M. , Wolk, Alicja

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 19, 2022 | Volume: 31 | Issue: 5 | Pages: 1077-1089

10.1158/1055-9965.epi-21-1003 | PMID 35438744 Get It

Abstract Background: Currently known associations between common genetic variants and colorectal cancer explain less than half of its heritability of 25%. As alcohol consumption has a J-shape association with colorectal cancer risk, nondrinking and heavy drinking are both risk factors for colorectal cancer. Methods: Individual-level data was pooled from the Colon Cancer Family Registry, Colorectal Transdisciplinary Study, and Genetics and Epidemiology of Colorectal Cancer Consortium to compare nondrinkers (≤1 g/day) and heavy drinkers (>28 g/day) with light-to-moderate drinkers (1–28 g/day) in GxE analyses. To improve power, we implemented joint 2df and 3df tests and a novel two-step method that modifies the weighted hypothesis testing framework. We prioritized putative causal variants by predicting allelic effects using support vector machine models. Results: For nondrinking as compared with light-to-moderate drinking, the hybrid two-step approach identified 13 significant SNPs with pairwise r2 > 0.9 in the 10q24.2/COX15 region. When stratified by alcohol intake, the A allele of lead SNP rs2300985 has a dose–response increase in risk of colorectal cancer as compared with the G allele in light-to-moderate drinkers [OR for GA genotype = 1.11; 95% confidence interval (CI), 1.06–1.17; OR for AA genotype = 1.22; 95% CI, 1.14–1.31], but not in nondrinkers or heavy drinkers. Among the correlated candidate SNPs in the 10q24.2/COX15 region, rs1318920 was predicted to disrupt an HNF4 transcription factor binding motif. Conclusions: Our study suggests that the association with colorectal cancer in 10q24.2/COX15 observed in genome-wide association study is strongest in nondrinkers. We also identified rs1318920 as the putative causal regulatory variant for the region. Impact: The study identifies multifaceted evidence of a possible functional effect for rs1318920.
DNA Sequencing Analysis of Cystic Fibrosis Transmembrane Regulator Gene Identifies Cystic Fibrosis-Associated Variants in the Severe Asthma Research Program.
Izquierdo, Manuel, Marion, Chad R. , Moore, Wendy C. , Raraigh, Karen S. , L, Jennifer Taylor-Cousar, Cutting, Garry R. , Ampleford, Elizabeth J., Hawkins, Gregory A., Zein, Joe , Denlinger, Loren C. , Erzurum, Serpil C. , Israel, Elliot , Jarjour, Nizar N. , Mauger, David, Woodruff, Prescott G. , Bleecker, Eugene R. , Meyers, Deborah A. , Ortega, Victor E. , Cutting, Gary R , Taylor‐Cousar, Jennifer L. , Castro, Mario , Fahy, John V. , Levy, Bruce David , Wenzel, Sally E.

Mayo Clinic

No container title available | April 19, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.165037325.52611651/v1 Get It

Background: Heterozygote carriers of potentially pathogenic variants in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene have increased asthma risk. However, the frequency and impact of CFTR variation among individuals with asthma is unknown. Objective: To determine whether potentially pathogenic CFTR variants associate with disease severity and whether individuals with two potentially pathogenic variants exist in a severe asthma-enriched cohort . Methods : We analyzed sequencing data spanning a 190.5Kb region of CFTR in participants from the Severe Asthma Research Program (SARP1-3). Potentially pathogenic, rare CFTR variants (frequency<0.05) were classified as CF-causing or of varying clinical consequences (VVCC) (CFTR2.org). Regression-based models tested for association between CFTR genotypes (0-2 potentially pathogenic variants) and severity outcomes. Results: Of 1401 participants, 9.5% (134) had one potentially pathogenic variant, occurring more frequently in non-Hispanic white (NHW, 10.1% [84 of 831]) compared to African American individuals (AA, 5.2% [22 of 426]). We found ≥2 potentially pathogenic CFTR variants in 1.4% (19); 0.5% (4) of NHW and 2.8% (12) of AA. Potentially pathogenic CFTR variant genotypes (≥1 or ≥2 variants) were not cumulatively associated with lung function or exacerbations. In NHW, we found three F508del compound heterozygotes with F508del and a VVCC (two 5T;TG12[c.1210-11T>G] and one Arg1070Trp) and a homozygote for the VVCC, 5T;TG12. Conclusions: We found potentially pathogenic CFTR variants within a severe asthma-enriched cohort , including three compound heterozygote genotypes variably associated with CF in NHW individuals. These findings provide the rationale for CFTR sequencing and phenotyping of CF-related traits in individuals with severe asthma.
The Onset–Offset N1–P2 Cortical Auditory Evoked Response in Individuals With High-Frequency Sensorineural Hearing Loss: Responses to High- and Low-Frequency Narrowband Noise
Gonzalez, Jennifer E. , Musiek, Frank E.

Mayo Clinic

American Journal of Audiology | April 18, 2022 | Volume: 31 | Issue: 2 | Pages: 359-369

10.1044/2022_aja-21-00124 | PMID 35436425 Get It

Purpose: This study aimed to determine whether onset–offset N1–P2 auditory evoked responses differ in amplitude, latency, and offset-to-onset trough-to-peak N1–P2 amplitude ratios (OOAR) between normal hearing (NH) sensitivity and moderate high-frequency sensorineural hearing loss (HFSNHL) groups when stimuli target regions of peripheral hearing sensitivity where the groups are in the normal range (i.e., 500 Hz) versus where they differ regarding presence of hearing loss (i.e., 4000 Hz). Method: Onset–offset N1–P2 auditory evoked responses were measured from 10 participants with normal hearing sensitivity and seven participants with moderate HFSNHL using 500-Hz and 4000-Hz narrowband noise (NBN) stimuli. Stimuli were 2000 ms with 40-ms rise-fall times presented at 50 dB SL referenced to stimulus behavioral thresholds. Amplitudes and latencies were analyzed for N1 and P2 onset and offset components via repeated measures analysis of variance (ANOVA). OOARs were compared between groups using one-way ANOVA and across stimuli per group using paired samples t tests. Results: Despite dB SPL stimulus presentation differences between groups, there were no significant differences in individual/absolute amplitude and latency waveform components between groups for either stimulus. Derived comparative calculations of OOAR for 4000-Hz NBN were significantly larger ( p < .025; NH: .39; HFSNHL: .62) for the group with HFSNHL than the group with NH sensitivity; 500-Hz NBN OOAR did not reach significance. OOARs revealed no significant difference between stimuli for the group with normal hearing sensitivity, with .38 OOAR for both stimuli ( p = .961). OOAR comparisons for the HFSNHL group across stimuli were significant ( p = .012), with the 4000-Hz NBN OOAR being nearly double the size of the 500-Hz NBN OOAR. Conclusions: OOARs may provide insight to the balance of excitatory and inhibitory neural firing in the central auditory nervous system (CANS). Larger OOARs may be a biomarker of reduced CANS inhibition, perhaps indicative of a homeostatic central auditory gain mechanism.
Longitudinal Correlates of Increased Alcohol Use Among Adolescents and Young Adults During the COVID-19 Pandemic
Sharma, Pravesh , Kamath, Celia , Geske, Jennifer R. , Prasad, Kavita, Holland, Ashely, Kurani, Shaheen , Pazdernik, Vanessa , Kremers, Hilal Maradit , St Sauver, Jennifer, Croarkin, Paul, Geske, Jennifer, Sharma, Pravesh , Kamath, Celia C , Geske, Jennifer , Sauver, Jennifer L. St. , Croarkin, Paul E. , Patten, Christi A.

Mayo Clinic

Alcohol and Alcoholism | April 18, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/alcalc/agac024 | PMID 35511126 Get It

Abstract Aims The objective of this study is to longitudinally assess sociodemographic and psychological correlates of increased alcohol use during the coronavirus disease of 2019 (COVID-19) period among adolescents and young adults. Methods Pre-COVID period is defined as the 1-year period on or before 31 March 2020, and during-COVID period is defined as the period from 1st April 2020 to 30 March 2021. Univariable logistic regression models are used to evaluate the association of demographic characteristics, Area Deprivation Index (ADI), rurality, changes in Patient Health Questionnaire (PHQ-9) and Generalized Anxiety Disorder (GAD-7) scale severity, and the risk of increased alcohol consumption (binge drinking, number of drinks and drinking regularity) from pre-COVID to during-COVID period. Results and conclusion Our study found that worsened anxiety symptoms, older age, being in college and current cigarette smoking status were associated with increased alcohol use among youth during the pandemic year. Socioeconomic position (measured by ADI) and rural status were not found to be associated with increased alcohol use among adolescents and young adults.
Complications and outcomes of posterior fossa decompression with duraplasty versus without duraplasty for pediatric patients with Chiari malformation type I and syringomyelia: a study from the Park-Reeves Syringomyelia Research Consortium
Akbari, S. Hassan A. , Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory W. , Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Bauer, David F. , Bethel-Anderson, Tammy, Bierbrauer, Karin S. , Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , Fuchs, Herbert E., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M. , Kaufman, Bruce A., Keating, Robert F., Khan, Nicklaus R., Krieger, Mark D., Leonard, Jeffrey R. , Maher, Cormac O. , Mangano, Francesco T. , McComb, J. Gordon , McEvoy, Sean D., Meehan, Thanda, Muhlbauer, Michael S., O’Neill, Brent R., Olavarria, Greg, Ragheb, John , Shannon, Chevis N. , Stone, Scellig , Strahle, Jennifer M. , Tamber, Mandeep S. , Torner, James C., Tuite, Gerald F. , Tyler‐Kabara, Elizabeth C. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Limbrick, David D. , Torner, James C. , Yahanda, Alexander T. , Ahmed, Raheel , Daniels, David J. , Dlouhy, Brian J , Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J., Jallo, George I. , Johnston, James M. , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Park, Tae Sung , Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | April 15, 2022 | Volume: 30 | Issue: 1 | Pages: 39-51

10.3171/2022.2.peds21446 | PMID 35426814 Get It

OBJECTIVE The aim of this study was to determine differences in complications and outcomes between posterior fossa decompression with duraplasty (PFDD) and without duraplasty (PFD) for the treatment of pediatric Chiari malformation type I (CM1) and syringomyelia (SM). METHODS The authors used retrospective and prospective components of the Park-Reeves Syringomyelia Research Consortium database to identify pediatric patients with CM1-SM who received PFD or PFDD and had at least 1 year of follow-up data. Preoperative, treatment, and postoperative characteristics were recorded and compared between groups. RESULTS A total of 692 patients met the inclusion criteria for this database study. PFD was performed in 117 (16.9%) and PFDD in 575 (83.1%) patients. The mean age at surgery was 9.86 years, and the mean follow-up time was 2.73 years. There were no significant differences in presenting signs or symptoms between groups, although the preoperative syrinx size was smaller in the PFD group. The PFD group had a shorter mean operating room time (p < 0.0001), fewer patients with > 50 mL of blood loss (p = 0.04), and shorter hospital stays (p = 0.0001). There were 4 intraoperative complications, all within the PFDD group (0.7%, p > 0.99). Patients undergoing PFDD had a 6-month complication rate of 24.3%, compared with 13.7% in the PFD group (p = 0.01). There were no differences between groups for postoperative complications beyond 6 months (p = 0.33). PFD patients were more likely to require revision surgery (17.9% vs 8.3%, p = 0.002). PFDD was associated with greater improvements in headaches (89.6% vs 80.8%, p = 0.04) and back pain (86.5% vs 59.1%, p = 0.01). There were no differences between groups for improvement in neurological examination findings. PFDD was associated with greater reduction in anteroposterior syrinx size (43.7% vs 26.9%, p = 0.0001) and syrinx length (18.9% vs 5.6%, p = 0.04) compared with PFD. CONCLUSIONS PFD was associated with reduced operative time and blood loss, shorter hospital stays, and fewer postoperative complications within 6 months. However, PFDD was associated with better symptom improvement and reduction in syrinx size and lower rates of revision decompression. The two surgeries have low intraoperative complication rates and comparable complication rates beyond 6 months.
Gerrymandering and Political Determinants of Health
Syed, Quratulain , Schmidt, Stacie , Powell, Rhea E. , Connolly, Nancy C. , Cowart, Jennifer B. , Newby, Celeste, Syed, Quratulain , Henry, Tracey L. , Connolly, Nancy

Mayo Clinic

Population Health Management | April 15, 2022 | Volume: 25 | Issue: 4 | Pages: 568-570

10.1089/pop.2021.0362 | PMID 35426738 Get It